Evidence
Independent laboratory testing, regulatory registration, intellectual property and competitively awarded research programmes behind Pathogen Capture Technology. Each entry links to its original source; underlying test reports are available under NDA.
Accreditation & IP
US FDA registration
Registered as a foreign manufacturing facility for the ABD Device. Owner/Operator Number 10074735.
View registration document (opens in a new tab)Accreditation & IP
Independent testing — NeoVirTech, France
Independent laboratory study of the ABD Device on human skin against SARS-CoV-2.
View test report (opens in a new tab)Accreditation & IP
International patent WO 2020/240027 A1
Device and method for decontamination / disinfection (WIPO).
View patent (PDF) (opens in a new tab)Accreditation & IP
ISO 13485
Certified quality system for medical device design and manufacture.
Peer-reviewed · 2025 · npj Microgravity
Muscle transcriptome profiling in mice exposed to microgravity
Read the paper (opens in a new tab)Peer-reviewed · 2018 · Methods in Cell Biology
A microfluidic fluidized bed to capture, amplify and detect bacteria from raw samples
Read the paper (opens in a new tab)Peer-reviewed · 2017 · Chemical Science
Microfluidic one-step capture, amplification and label-free quantification of bacteria
Read the paper (opens in a new tab)Peer-reviewed · 2017 · Scientific Reports
Screening of a 78-species avian egg white glycoprotein microarray
Read the paper (opens in a new tab)Peer-reviewed · 2016 · Journal of Bioterrorism & Biodefense
Exploitation of glycobiology in anti-adhesion approaches against biothreat agents
Read the paper (opens in a new tab)Peer-reviewed · 2015 · Microarrays (MDPI)
Bacterial interactions studied using carbohydrate-based microarrays
Read the paper (opens in a new tab)Competitive funding · 01/2025 – 06/2026
European Space Agency
Development and validation of protein–carbohydrate pathogen capture technology for space flight decontamination.
€175,000
Competitive funding · 07/2020 – 01/2023
EIC Accelerator · Grant 959436
COVID-19 bio-decontamination technology.
EU contribution €1,941k of a €2,773k budget
Competitive funding · 04/2017 – 04/2021
ITN PathSense
Student secondments only.
No cost to Aquila
Competitive funding · 01/2018 – 06/2018
Glyco-DeCon Feasibility Study
Feasibility and IP review.
€71k
Competitive funding · 04/2015 – 04/2017
DCLAW · European Defence Agency
Biothreat agent capture.
Aquila cost €132k of a €248k total
Competitive funding · 05/2014 – 04/2017
NAPES · EU FP7-NMP
Environmental sensing platforms.
Aquila cost €480k of a €4,539k total
Press · University of Galway
Protecting lives while harnessing the power of nature
Read the article (opens in a new tab)Press · Silicon Republic
Aquila Bioscience collaborates with European Space Agency
Read the article (opens in a new tab)Press · Silicon Republic
Muscle atrophy in microgravity environment and multi-omic data analysis
Read the article (opens in a new tab)Press · Newstalk · Futureproof
Research on pathogen decontamination in microgravity
Read the article (opens in a new tab)Press · Company update · 20–23 March 2025
Aquila Bioscience and Innov8 Labs shortlisted as finalists for the Cosmopack Awards, Cosmoprof Worldwide Bologna
Press · Galway Advertiser
Local medtech company develops mask spray which blocks 99 per cent of pathogens
Read the article (opens in a new tab)Press · Silicon Republic
Galway medtech develops mask spray to block 99% of pathogens
Read the article (opens in a new tab)Press · HEA · 27 May 2020
Higher Education research activity in response to SARS-CoV-2
Read the article (opens in a new tab)Press · The Irish Times
Innovation is key in battle against Covid-19
Read the article (opens in a new tab)Press · NUI Galway · January 2020
Irish innovation in wipes and masks could help battle emerging coronavirus crisis
Read the article (opens in a new tab)Press · GRIPT
An emerging Irish technology may be key to containing the Wuhan coronavirus
Read the article (opens in a new tab)
Request the evidence pack.
Capture data, organism lists and study reports are shared with prospective partners under NDA.